Publicly Traded Hemp-Focused Wellness Company Reports Q2 Results, Here Is What You Need To Know
CV Sciences Inc Q1 Revenue Stagnates YoY, Here Is What You Need To Know
CV Sciences FY22 Revenue Declines 19% To $16.2M
CBD And Nicotine Formula To Treat Smokeless Tobacco Addiction Receives Patent From Japan, FDA Approval Next
Joseph Dowling Recent News
Why Is CV Sciences Stock Up Today?
EXCLUSIVE: Keep Calm And Carry CBD Softgels With THC, CV Sciences Launches Relaxation Products
CV Sciences Q1 Revenue Down 8.33%, CEO Encouraged As PlusCBD Brand Gains Market Share
CV Sciences Adds +PlusCBD Relief Softgels To Wellness Line Of CBD Products
CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients
CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation